DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals (NYSE MKT:NAVB) reports financial results for the quarter ending September 30, 2016. Navidea reported total revenue for the third quarter of 2016 of $8.5 million, including Lymphoseek® (technetium Tc 99m tilmanocept) injection sales revenue of $6.7 million. The income from operations was $3.4 million and the net loss attributable to common stockholders was $59,000.
